Clinical Trial	# of vaccinees analyzed	# of mAbs	% Long HCDR3	Comparison of frequency of long HCDR3 mAbs	P value
RV144 boosts	4	242	20.7%	RV144 boosts vs HVTN 505	< 0.05
HVTN 505	8	221	4.1%	RV144 boosts vs GSK PRO HIV - 002	< 0.05
GSK PRO HIV - 002	4	58	6.9%	HVTN 505 vs GSK PRO HIV - 002	0.48066